ATE400297T1 - Ctgf als zielmolekül in der behandlung von mikroalbuminurie in patienten mit diabetischer nephropathie - Google Patents

Ctgf als zielmolekül in der behandlung von mikroalbuminurie in patienten mit diabetischer nephropathie

Info

Publication number
ATE400297T1
ATE400297T1 AT05713358T AT05713358T ATE400297T1 AT E400297 T1 ATE400297 T1 AT E400297T1 AT 05713358 T AT05713358 T AT 05713358T AT 05713358 T AT05713358 T AT 05713358T AT E400297 T1 ATE400297 T1 AT E400297T1
Authority
AT
Austria
Prior art keywords
diabetic nephropathy
microalbuminuria
ctgf
patients
treatment
Prior art date
Application number
AT05713358T
Other languages
English (en)
Inventor
Allan Flyvbjerg
Guangjie Guo
David Liu
Thomas Neff
Noelynn Oliver
William Usinger
Qingjian Wang
Original Assignee
Fibrogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fibrogen Inc filed Critical Fibrogen Inc
Application granted granted Critical
Publication of ATE400297T1 publication Critical patent/ATE400297T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/556—Angiotensin converting enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Apparatus For Radiation Diagnosis (AREA)
AT05713358T 2004-02-11 2005-02-11 Ctgf als zielmolekül in der behandlung von mikroalbuminurie in patienten mit diabetischer nephropathie ATE400297T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US54412104P 2004-02-11 2004-02-11
US56101804P 2004-04-08 2004-04-08
US57840104P 2004-06-09 2004-06-09
US62080204P 2004-10-20 2004-10-20

Publications (1)

Publication Number Publication Date
ATE400297T1 true ATE400297T1 (de) 2008-07-15

Family

ID=34865408

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05713358T ATE400297T1 (de) 2004-02-11 2005-02-11 Ctgf als zielmolekül in der behandlung von mikroalbuminurie in patienten mit diabetischer nephropathie

Country Status (14)

Country Link
US (2) US20050214294A1 (de)
EP (2) EP1977762A1 (de)
CN (1) CN101884789A (de)
AT (1) ATE400297T1 (de)
AU (1) AU2005212371B2 (de)
CA (1) CA2555789A1 (de)
DE (1) DE602005008013D1 (de)
DK (1) DK1715890T3 (de)
ES (1) ES2311973T3 (de)
IL (1) IL177437A (de)
NZ (1) NZ549784A (de)
PL (1) PL1715890T3 (de)
PT (1) PT1715890E (de)
WO (1) WO2005077413A1 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2342280A1 (en) * 1998-09-08 2000-03-16 Henry Ford Health System Methods for detecting, preventing, and treating renal disorders by modulating, regulating, and inhibiting connective tissue growth factor
EP1885756A2 (de) 2005-05-05 2008-02-13 Fibrogen, Inc. Therapien von gefässkrankheit
US8372886B2 (en) * 2005-12-22 2013-02-12 Kiacta Sarl Treatment of renal disorders, diabetic nephropathy and dyslipidemias
MX2009006768A (es) * 2006-12-22 2009-08-31 Bellus Health Int Ltd Metodos, compuestos, y composiciones para tratar trastornos metabolicos y diabetes.
JP2010536880A (ja) 2007-08-22 2010-12-02 ギリード・コロラド・インコーポレーテッド 糖尿病の合併症のための療法
US8946172B2 (en) 2008-08-25 2015-02-03 Excaliard Pharmaceuticals, Inc. Method for reducing scarring during wound healing using antisense compounds directed to CTGF
EP3081648A1 (de) 2008-08-25 2016-10-19 Excaliard Pharmaceuticals, Inc. Gegen den bindegewebe-wachstumsfaktor gerichtete antisense-oligonukleotide und verwendungen davon
SI2670411T1 (sl) 2011-02-02 2019-06-28 Excaliard Pharmaceuticals, Inc. Protismiselne spojine, ki so usmerjene na rastni faktor veznega tkiva (CTGF), za uporabo v postopku zdravljenja keloidov ali hipertrofnih brazgotin
KR102339724B1 (ko) 2013-11-28 2021-12-17 씨에스엘 리미티드 신장병증의 치료 방법
CN111033637B (zh) 2017-08-08 2023-12-05 费森尤斯医疗保健控股公司 用于治疗和评估慢性肾脏疾病的进程的系统和方法
CN112512532B (zh) * 2018-07-31 2024-11-08 雷莫内克斯生物制药有限公司 用于抑制ctgf表达的组合物
CN109402127B (zh) * 2018-09-29 2021-12-10 复旦大学附属眼耳鼻喉科医院 一组与结缔组织生长因子特异性结合的高亲和力核酸适配体及其应用
CN109453191A (zh) * 2018-12-06 2019-03-12 郑州大学第附属医院 GSK-3β抑制剂及在糖尿病肾病干预新靶点的应用
BR112021023669A2 (pt) * 2019-06-04 2022-03-29 Jiangsu Hengrui Medicine Co Anticorpo do fator de crescimento de tecido anti-conjuntivo e aplicação do mesmo

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5408040A (en) * 1991-08-30 1995-04-18 University Of South Florida Connective tissue growth factor(CTGF)
US5770209A (en) 1991-08-30 1998-06-23 University Of South Florida Acceleration of wound healing using connective tissue growth factor
US5876730A (en) 1997-08-07 1999-03-02 Childrens Hospital Research Foundation Heparin-binding growth factor (HBGF) polypeptides
WO1999033878A1 (en) 1997-12-25 1999-07-08 Japan Tobacco Inc. Monoclonal antibody against connective tissue growth factor and medicinal uses thereof
AU4976599A (en) 1998-07-08 2000-02-01 Fibrogen, Inc. Method for treatment of fibrosis related diseases by the administration of prostacyclin derivatives
CA2342280A1 (en) * 1998-09-08 2000-03-16 Henry Ford Health System Methods for detecting, preventing, and treating renal disorders by modulating, regulating, and inhibiting connective tissue growth factor
AU765133B2 (en) 1998-11-06 2003-09-11 Fibrogen, Inc. Connective tissue growth factor (CTGF) and methods of use
US6348329B1 (en) * 1998-11-06 2002-02-19 Fibrogen, Inc. Nucleic acids encoding rat connective tissue growth factor (CTGF) and methods of use
CN1170849C (zh) * 1998-12-14 2004-10-13 迈阿密大学 结缔组织生长因子片段及其方法和用途
US6706491B1 (en) 1999-04-09 2004-03-16 The Board Of Trustees Of The University Of Illinois Reagents and methods for identifying and modulating expression of genes regulated by p21
US6965025B2 (en) 2001-12-10 2005-11-15 Isis Pharmaceuticals, Inc. Antisense modulation of connective tissue growth factor expression
ATE526041T1 (de) * 2001-12-11 2011-10-15 Fibrogen Inc Verfahren zur hemmung okularer vorgänge
WO2003092584A2 (en) 2002-04-30 2003-11-13 Alcon, Inc. Agents which regulate, inhibit, or modulate the activity and/or expression of connective tissue growth factor (ctgf) as a unique means to both lower intraocular pressure and treat glaucomatous retinopathies/optic neuropathies
US7405274B2 (en) 2003-06-04 2008-07-29 Fibrogen, Inc. Connective tissue growth factor antibodies
WO2005038013A1 (en) 2003-10-07 2005-04-28 Isis Pharmaceuticals, Inc. Artisense oligonucleotides optimized for kidney targeting

Also Published As

Publication number Publication date
EP1977762A1 (de) 2008-10-08
WO2005077413A1 (en) 2005-08-25
PL1715890T3 (pl) 2009-01-30
NZ549784A (en) 2008-06-30
DE602005008013D1 (de) 2008-08-21
US8314059B2 (en) 2012-11-20
EP1715890B1 (de) 2008-07-09
PT1715890E (pt) 2008-10-17
ES2311973T3 (es) 2009-02-16
US20100291098A1 (en) 2010-11-18
CN101884789A (zh) 2010-11-17
CA2555789A1 (en) 2005-08-25
DK1715890T3 (da) 2008-11-17
US20050214294A1 (en) 2005-09-29
AU2005212371B2 (en) 2010-05-13
AU2005212371A1 (en) 2005-08-25
IL177437A0 (en) 2006-12-10
EP1715890A1 (de) 2006-11-02
HK1095762A1 (en) 2007-05-18
IL177437A (en) 2013-06-27

Similar Documents

Publication Publication Date Title
CY1123084T1 (el) Θεραπεια των ασθενειων αποθηκευσης γλυκογονου τυπου ιι
ATE400297T1 (de) Ctgf als zielmolekül in der behandlung von mikroalbuminurie in patienten mit diabetischer nephropathie
BR0308928A (pt) Uso de toxina botulìnica para o tratamento de doenças cardiovasculares, bem como composição para uso em um procedimento cardiovascular
ATE521608T1 (de) Glucokinaseaktivatoren
DK1615952T3 (da) Fremgangsmåder til behandling af betændelsestilstande med specifikke, til humant angiopoietin-2-bindende midler
EA200802213A1 (ru) Способы лечения заболеваний крови
NO20074999L (no) Metode og preparat for behandling av perifere vaskulaere sykdommer
EA200501771A1 (ru) Лиганды каннабиноидных рецепторов и их применения
EA200900802A1 (ru) Способы и композиции для лечения амилоидных заболеваний
ATE432693T1 (de) Kombinationstherapie zur behandlung von diabetes und dadurch bedingten leiden sowie zur behandlung von mittels erhöhung des glp-1-spiegels im blut verbesserten leiden
ATE427759T1 (de) Behandlung von fettsucht und verbundenen erkrankungen
EA200700175A1 (ru) Композиции и способы лечения воспалительных заболеваний
MA28935B1 (fr) Preparation et utilisation de derives de biphenyl-4-yl-carbonylamino-acide dans le traitement de l'obesite
ATE552000T1 (de) Verwendung von isothiocyanat-verbindungen zur behandlung von prostata-erkrankungen und hautkrebs
DE602005022113D1 (de) Phenyl)methanon-derivate als glycin-transporter 1 (glyt-1) hemmer zur behandlung von neurologischen und neuropsychiatrischen erkrankungen
NO20076121L (no) Behandlinger for kardiovaskulaer sykdom
DE602005017241D1 (de) Behandlung von Gewichtsverlust bei Patienten mit entzündlichen Darmerkrankungen mittels S. boulardii
ATE424386T1 (de) Pyridin-verbindungen für die behandlung von prostaglandin-vermittelten krankheiten
NO20033949L (no) Sammensetning og fremgangsmåte til å behandle neoplastiske sykdommer assosiert med forhöyede matriks metalloproteinaseaktiviteter ved åbenytte katechinforbindelser
ATE462702T1 (de) Für die behandlung von entzündlichen krankheiten nützliche beta-carboline
EA201000630A1 (ru) Применение бензоконденсированных гетероциклических сульфамидных производных для понижения уровней липидов в крови
EA200700407A1 (ru) Производные хиназолина и их использования при лечении тромбоцитемии
DE602005017626D1 (de) Antivirale verwendung von borinsäurekomplexen
DE602008004556D1 (de) Zusammensetzungen und verfahren zum nachweis von störungen in verbindung mit histamin
DK1596879T3 (da) Anvendelse af kahalalidforbindelser til fremstilling af et medikament til behandling af psoriasis

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1715890

Country of ref document: EP